Background: The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed.
Methods: The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate.
Results: The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity.
Conclusions: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.
Keywords: COVID-19; ELISA; SARS-CoV-2; diagnosis; serological test.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: firstname.lastname@example.org.
Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection.Clin Infect Dis. 2020 May 1:ciaa523. doi: 10.1093/cid/ciaa523. Online ahead of print. Clin Infect Dis. 2020. PMID: 32357209 Free PMC article.
Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.J Appl Lab Med. 2020 May 19:jfaa079. doi: 10.1093/jalm/jfaa079. Online ahead of print. J Appl Lab Med. 2020. PMID: 32428207
Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8. doi: 10.1128/CDLI.11.4.665-668.2004. Clin Diagn Lab Immunol. 2004. PMID: 15242938 Free PMC article.
COVID-19 (Novel Coronavirus 2019) - recent trends.Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2006-2011. doi: 10.26355/eurrev_202002_20378. Eur Rev Med Pharmacol Sci. 2020. PMID: 32141569 Review.
Diagnostic performance of COVID-19 serology assays.Malays J Pathol. 2020 Apr;42(1):13-21. Malays J Pathol. 2020. PMID: 32342927 Review.
Cited by 2 articles
[Statement of the Austrian Society of Pneumology (ASP)].Wien Klin Mag. 2020 May 18:1-22. doi: 10.1007/s00740-020-00350-4. Online ahead of print. Wien Klin Mag. 2020. PMID: 32427192 Free PMC article. Review. German.
[COVID-19 in hospitalized children and adolescents].Monatsschr Kinderheilkd. 2020 Apr 21:1-12. doi: 10.1007/s00112-020-00919-7. Online ahead of print. Monatsschr Kinderheilkd. 2020. PMID: 32317808 Free PMC article. Review. German.